Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.97 USD | -0.30% | -7.19% | +64.23% |
May. 14 | Enliven Therapeutics Q1 Loss Narrows | MT |
Apr. 11 | Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | CI |
Official Publications
No official publication found
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Official Publications